Expression of constitutive androstane receptor, hepatic nuclear factor 4α, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver

Drug Metabolism and Disposition

Volumn 35, Issue 9, 2007, Pages 1700-1710

  Wortham, Matthew ^a   Czerwinski, Maciej ^b   He, Lin ^a   Parkinson, Andrew ^b   Wan, Yu Jui Yvonne ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b XenoTech LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 REDUCTASE; GLUCURONOSYLTRANSFERASE 1A1; HEPATIC NUCLEAR FACTOR 4ALPHA; LIVER PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; LIVER; MALE; METABOLIC REGULATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; INFANT; INFANT, NEWBORN; ISOENZYMES; LIVER; MALE; MICROSOMES, LIVER; MIDDLE AGED; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; XENOBIOTICS;

EID: 34548082616     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016436     Document Type: Article

References (40)

1. Al-Dosari MS, Knapp JE, and Liu D (2006) Activation of human CYP2C9 promoter and regulation by CAR and PXR in mouse liver. Mol Pharm 3:322-328.
2. Bogacka I, Ukropcova B, McNeil M, Gimble JM, and Smith SR (2005) Structural and functional consequences of mitochondrial biogenesis in human adipocytes in vitro. J Clin Endocrinol Metab 90:6650-6656.
3. Carlberg C and Dunlop TW (2006) An integrated biological approach to nuclear receptor signaling in physiological control and disease. Crit Rev Eukaryot Gene Expr 16:1-22.
4. Chang TK, Bandiera SM, and Chen J (2003) Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 31:7-10.
5. Chen Y, Ferguson SS, Negishi M, and Goldstein JA (2003) Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 64:316-324.
6. Ding X, Lichti K, Kim I, Gonzalez FJ, and Staudinger JL (2006) Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha. J Biol Chem 281:26540-26551.
7. Endrizzi K, Fischer J, Klein K, Schwab M, Nussler A, Neuhaus P, Eichelbaum M, and Zanger UM (2002) Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. Anal Biochem 300:121-131.
8. Evans WE and Relling MV (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468.
9. Ferguson SS, Chen Y, LeCluyse EL, Negishi M, and Goldstein JA (2005) Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 68:747-757.
10. Finkelstein D, Lamba V, Assem M, Rengelshausen J, Yasuda K, Strom S, and Schuetz E (2006) ADME transcriptome in Hispanic versus White donor livers: evidence of a globally enhanced NR1I3 (CAR, constitutive androstane receptor) gene signature in Hispanics. Xenobiotica 36:989-1012.
11. Honkakoski P, Zelko I, Sueyoshi T, and Negishi M (1998) The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 18:5652-5658.
12. Ingelman-Sundberg M, Oscarson M, and McLellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342-349.
13. Jover R, Bort R, Gomez-Lechon MJ, and Castell JV (2001) Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 33:668-675.
14. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, and Edwards PA (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908-2915.
15. Kawashima S, Kobayashi K, Takama K, Higuchi T, Furihata T, Hosokawa M, and Chiba K (2006) Involvement of hepatocyte nuclear factor 4alpha in the different expression level between CYP2C9 and CYP2C19 in the human liver. Drug Metab Dispos 34:1012-1018.
16. Koop DR and Tierney DJ (1990) Multiple mechanisms in the regulation of ethanol-inducible cytochrome P450IIE1. Bioessays 12:429-435.
17. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, et al. (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906-922.
18. Madan A, DeHaan R, Mudra D, Carroll K, LeCluyse E, and Parkinson A (1999) Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. Drug Metab Dispos 27:327-335.
19. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, et al. (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431.
20. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, and Kliewer SA (2002) Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62:638-646.
21. Obach RS, Zhang QY, Dunbar D, and Kaminsky LS (2001) Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab Dispos 29:347-352.
22. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, et al. (2004) Control of pancreas and liver gene expression by HNF transcription factors. Science 303:1378-1381.
23. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, and Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388.
24. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
25. Pandey AV (2006) Biochemical analysis of mutations in P450 oxidoreductase. Biochem Soc Trans 34:1186-1191.
26. Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, Ning G, Kaestner KH, Rossi JM, Zaret KS, and Duncan SA (2003) Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet 34:292-296.
27. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, and Vilarem MJ (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268:6346-6358.
28. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Assenat E, Larrey D, Pichard-Garcia L, Vilarem MJ, and Maurel P (2004) Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. Xenobiotica 34:633-664.
29. Pascussi JM, Gerbal-Chaloin S, Fabre JM, Maurel P, and Vilarem MJ (2000) Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 58:1441-1450.
30. Rodriguez-Antona C, Donato MT, Pareja E, Gomez-Lechon MJ, and Castell JV (2001) Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 393:308-315.
31. Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N, Colinayo V, Ruff TG, Milligan SB, Lamb JR, Cavet G, et al. (2003) Genetics of gene expression surveyed in maize, mouse and man. Nature 422:297-302.
32. Slatter JG, Templeton IE, Castle JC, Kulkarni A, Rushmore TH, Richards K, He Y, Dai X, Cheng OJ, Caguyong M, et al. (2006) Compendium of gene expression profiles comprising a baseline model of the human liver drug metabolism transcriptome. Xenobiotica 36:938-962.
33. Staudinger JL, Madan A, Carol KM, and Parkinson A (2003) Regulation of drug transporter gene expression by nuclear receptors. Drug Metab Dispos 31:523-527.
34. Sugatani J, Kojima H, Ueda A, Kakizaki S, Yoshinari K, Gong QH, Owens IS, Negishi M, and Sueyoshi T (2001) The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 33:1232-1238.
35. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475-490.
36. Wisely GB, Miller AB, Davis RG, Thornquest AD, Jr., Johnson R, Spitzer T, Sefler A, Shearer B, Moore JT, et al. (2002) Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure 10:1225-1234.
37. Wu L, Gu J, Cui H, Zhang QY, Behr M, Fang C, Weng Y, Kluetzman K, Swiatek PJ, Yang W, et al. (2005) Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 312:35-43.
38. Xu C, Li CY, and Kong AN (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharmacol Res 28:249-268.
39. Yengi LG, Xiang Q, Pan J, Scatina J, Kao J, Ball SE, Fruncillo R, Ferron G, and Roland Wolf C (2003) Quantitation of cytochrome P450 mRNA levels in human skin. Anal Biochem 316:103-110.
40. Yvert G, Brem RB, Whittle J, Akey JM, Foss E, Smith EN, Mackelprang R, and Kruglyak L (2003) Trans-acting regulatory variation in Saccharomyces cerevisiae and the role of transcription factors. Nat Genet 35:57-64.